- Home
- CNTA vs ACAD Comparison
CNTA vs ACAD Comparison
Compare CNTA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- ACAD
- Stock Information
- Founded
- CNTA 2020
- ACAD 1993
- Country
- CNTA United Kingdom
- ACAD United States
- Employees
- CNTA N/A
- ACAD N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- CNTA Health Care
- ACAD Health Care
- Exchange
- CNTA Nasdaq
- ACAD Nasdaq
- Market Cap
- CNTA 2.2B
- ACAD 2.6B
- IPO Year
- CNTA 2021
- ACAD 2004
- Fundamental
- Price
- CNTA $18.19
- ACAD $16.22
- Analyst Decision
- CNTA Strong Buy
- ACAD Buy
- Analyst Count
- CNTA 7
- ACAD 19
- Target Price
- CNTA $23.71
- ACAD $26.44
- AVG Volume (30 Days)
- CNTA 527.9K
- ACAD 1.4M
- Earning Date
- CNTA 11-12-2024
- ACAD 11-06-2024
- Dividend Yield
- CNTA N/A
- ACAD N/A
- EPS Growth
- CNTA N/A
- ACAD N/A
- EPS
- CNTA N/A
- ACAD 0.78
- Revenue
- CNTA $6,853,000.00
- ACAD $929,236,000.00
- Revenue This Year
- CNTA N/A
- ACAD $35.78
- Revenue Next Year
- CNTA N/A
- ACAD $8.58
- P/E Ratio
- CNTA N/A
- ACAD $20.89
- Revenue Growth
- CNTA N/A
- ACAD 47.06
- 52 Week Low
- CNTA $5.58
- ACAD $14.15
- 52 Week High
- CNTA $18.74
- ACAD $32.59
- Technical
- Relative Strength Index (RSI)
- CNTA 64.61
- ACAD 46.93
- Support Level
- CNTA $15.00
- ACAD $16.37
- Resistance Level
- CNTA $18.74
- ACAD $18.71
- Average True Range (ATR)
- CNTA 1.18
- ACAD 0.74
- MACD
- CNTA 0.10
- ACAD -0.08
- Stochastic Oscillator
- CNTA 85.29
- ACAD 31.51
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.